Adjuvant Therapy of Pancreatic Cancer

  • Chakra P Chaulagain Division of Hematology and Oncology, Tufts Medical Center and Tufts University School of Medicine. Boston, MA, USA
  • John Ng Weill Cornell Medical College and Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital. New York, NY, USA
  • David Wazer Department of Radiation Oncology, Tufts Medical Center and Tufts University School of Medicine. Boston, MA, USA
  • Muhammad Wasif Saif Division of Hematology and Oncology, Tufts Medical Center and Tufts University School of Medicine. Boston, MA, USA
DOI: https://doi.org/10.6092/1590-8577/935
Keywords: Chemotherapy, Adjuvant, Immunotherapy, Pancreatic Neoplasms

Abstract

Adjuvant therapy for pancreatic cancer remains controversial. However, both sides of the Atlantic Ocean agree that at least gemcitabine should be the pivotal agent offered to all patients. The role of radiation therapy remains somewhat inconclusive but chemoradiation, whether in the neoadjuvant or adjuvant setting is a standard option often utilized in the USA. This review is an update from the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, USA. We present the summary of the findings from Abstracts #4020, #4021, #4040 and #4049 and discuss the impact on this group of patients.

Image: Dose distributions of photons and protons.

 

Downloads

Download data is not yet available.

References

Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Deshpande V, et al. Phase I/II study of preoperative (pre-op) short course chemoradiation (CRT) with proton beam therapy (PBT) and capecitabine (cape) followed by early surgery for resectable pancreatic ductal adenocarcinoma (PDAC) of the head. J Clin Oncol 2012; 30(Suppl):Abstract 4021.

Alvarez-Gallego R, Cubillo A, Rodriguez-Pascual J, Quijano Y, De Vicente E, García L, et al. Antitumor activity of nab-paclitaxel and gemcitabine in resectable pancreatic cancer. J Clin Oncol 2012; 30(Suppl):Abstract 4040.

Hardacre JM, Mulcahy MF, Small W, Talamonti MS, Obel JC, Rocha Lima CMS, et al. Addition of algenpantucel-L immunotherapy to standard of care (SOC) adjuvant therapy for pancreatic cancer. J Clin Oncol 2012; 30(Suppl):Abstract 4049.

Sinn M, Sinn BV, Striefler JK, Stieler J, Niedergethmann M, Gellert K, et al. Long-term survival in patients with pancreatic cancer: Relevant factors in CONKO-001. J Clin Oncol 2012; 30(Suppl):Abstract 4020.

Steinberg ML, Konski A. Proton beam therapy and the convoluted pathway to incorporating emerging technology into routine medical care in the United States. Cancer J. 2009;15:333-8.

Koido et a. Current Immunotherapeutic Approaches in Pancreatic Cancer. Clinical and Developmental Immunology. June, 2011

Saif MW. JOP. J Pancreas (Online) 2011 Mar 9; 12(2):106-109. Adjuvant Therapy of Pancreatic Cancer: Beyond Gemcitabine. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011

Hardacre et. Al. Effect of the addition of algenpantucel-L immunotherapy to standard adjuvant therapy on survival in patients with resected pancreas cancer. J Clin Oncol 2011; 29(Suppl 4):Abstract 236.

Herman et a. Correlation of DPC4 status with outcomes in pancreatic adenocarcinoma patients receiving adjuvant chemoradiation. J Clin Oncol 2011; 29(Suppl 4):Abstract 168.

Dose distributions of photons and protons
Published
2012-07-10
How to Cite
ChaulagainC., NgJ., WazerD., & SaifM. (2012). Adjuvant Therapy of Pancreatic Cancer. JOP. Journal of the Pancreas, 13(4), 349-353. https://doi.org/10.6092/1590-8577/935
Issue
Vol 13 No 4 (2012): July - p. 330-469
Section
Highlights from the “2012 ASCO Annual Meeting”. Chicago, IL, USA. June 1-5, 2012

Copyright (c) 2014 Chakra P Chaulagain, John Ng, David Wazer, Muhammad Wasif Saif

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.

Most read articles by the same author(s)